EUVIMEDDescoperă EUVIMED
Leserbrief

Novel immunotherapeutic approaches for pediatric classical Hodgkin lymphoma: Nivolumab or brentuximab vedotin with the AVD regimen

Olayinka Okeleji iD, Amber Gibson iD, Cesar Nunez, Miriam B Garcia iD, Michael Roth iD, Branko Cuglievan, David McCall iD

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.31091 ↗

At a glance

Leserbrief in Pediatric Blood & Cancer, 2024. Written by Olayinka Okeleji and 6 co-authors. Institution: Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Major MEDLINE topics: Brentuximab Vedotin, Hodgkin Disease, Nivolumab, Antineoplastic Combined Chemotherapy Protocols. 10 references.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

To the Editor: Combination chemotherapy and radiation therapy have been the standard treatment of classical Hodgkin lymphoma (cHL) in pediatric patients, achieving a 5-year overall survival (OS) rate of 95%.1, 2 Over the past decade, two notable targeted therapeutics (brentuximab vedotin [BV] and nivolumab) have gained U.S. Food and Drug Administration approval for newly diagnosed and relapsed/refractory cHL, respectively.3, 4 These two agents have been studied with different chemotherapy backbones, but most recently, AVD (doxorubicin, vinblastine, and dacarbazine). BV, a CD30 targeted antibody–drug conjugate, and nivolumab, an anti-PD-1 antibody, when combined with AVD, have excellent efficacy (86% and 94% progression-free survival [PFS], respectively) and safety profiles in adult and pediatric patients with newly diagnosed cHL.5 BV–AVD plus radiation has also been employed in frontline settings for early-stage unfavorable cHL, producing promising results with four cycles, with a 1-year PFS of 93%. Using these data to guide management, we describe three pediatric patients (age 12 years old) in the recent SouthWest Oncology Group (SWOG) 1826 study, incorporation of these novel agents with a more traditional adult chemotherapy backbone for younger children (

Subjects

MeSH terms (MEDLINE)

Brentuximab VedotinHodgkin DiseaseNivolumabAntineoplastic Combined Chemotherapy ProtocolsHumansChildMaleFemaleAntineoplastic Agents, ImmunologicalAdolescentImmunotherapyDoxorubicinVinblastine

Substances

Brentuximab VedotinNivolumabAntineoplastic Agents, ImmunologicalDoxorubicinVinblastine

Authors and institutions

  • Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID profiles: Olayinka Okeleji, Amber Gibson, Miriam B Garcia, Michael Roth, David McCall

Cite

APA

Okeleji, O., Gibson, A., Nunez, C., Garcia, M. B., Roth, M., Cuglievan, B., & McCall, D. (2024). Novel immunotherapeutic approaches for pediatric classical Hodgkin lymphoma: Nivolumab or brentuximab vedotin with the AVD regimen. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31091

Vancouver

Okeleji O, Gibson A, Nunez C, Garcia MB, Roth M, Cuglievan B, et al. Novel immunotherapeutic approaches for pediatric classical Hodgkin lymphoma: Nivolumab or brentuximab vedotin with the AVD regimen. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31091

BibTeX
@article{Okeleji2024,
  author = {Okeleji, Olayinka and Gibson, Amber and Nunez, Cesar and Garcia, Miriam B and Roth, Michael and Cuglievan, Branko and McCall, David},
  title = {Novel immunotherapeutic approaches for pediatric classical Hodgkin lymphoma: Nivolumab or brentuximab vedotin with the AVD regimen},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.31091}
}
Start for free →